The platelet-derived growth factor receptor as a target for vascular endothelial growth factor-mediated anti-angiogenetic therapy in head and neck cancer

International Journal of Oncology

Volumn 34, Issue 1, 2009, Pages 255-261

  Bran, Birgit ^a   Bran, Gregor ^a   Hörmann, Karl ^a   Riedel, Frank ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Angiogenesis; Head andneck cancer; Imatinib (Gleevec, STI571); Plateled derived growth factor; Vascular endothelial growth factor

Indexed keywords

IMATINIB; PLATELET DERIVED GROWTH FACTOR RECEPTOR; VASCULOTROPIN; ANTINEOPLASTIC AGENT; MESSENGER RNA; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE; UNCLASSIFIED DRUG; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADULT; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; ARTICLE; AUTOCRINE EFFECT; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CANCER PATIENT; CELL CULTURE; CONTROLLED STUDY; DOWN REGULATION; DRUG TARGETING; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; PARACRINE SIGNALING; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; DRUG ANTAGONISM; GENETICS; HEAD AND NECK TUMOR; METABOLISM; MIDDLE AGED; NEOVASCULARIZATION (PATHOLOGY); SQUAMOUS CELL CARCINOMA; TUMOR CELL CULTURE; VASCULARIZATION;

ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; PIPERAZINES; PYRIMIDINES; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 60749116442     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000147     Document Type: Article

References (43)

1. Shibuya K, Mathers CD, Boschi-Pinto C, Lopez AD and Murray CJ: Global and regional estimates of cancer mortality and incidence by site: II. Results for the global burden of disease 2000. BMC Cancer 2: 37, 2002.
2. Ries LAG, Eisner MP, Kosary CL, Hankey BF, Miller BA, Clegg L, et al: SEER Cancer Statistics Review, 1975-2002. National Cancer Institute, Bethesda, MD, 2005.
3. Dimery IW and Hong WK: Overview of combined modality therapies for head and neck cancer. J Natl Cancer Inst 85: 95-111, 1993.
4. Folkman J: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1: 27-31, 1995.
5. Riedel F, Götte K, Schwalb J, Bergler W and Hörmann K: Coexpression of VEGF and bFGF is associated with increased vascular density in head and neck carcinomas. Laryngorhinootologie 79: 730-735, 2000.
6. Risau W: Mechanisms of angiogenesis. Nature 386: 671-674, 1997.
7. Folkman J and Klagsbrun M: Angiogenetic Factors. Science 235: 442-447, 1987.
8. Dvorak HF, Brown LF, Detmar M and Dvorak HM: Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability and angiogenesis. Am J Pathol 146: 1029-1039, 1995.
9. Ferrara N: The role of vascular endothelial growth factor in pathological angiogenesis. Breast Cancer Res Treat 36: 127-137, 1995.
10. Zhang HT, Craft P, Scott PA, Ziche M, Weich HA, Harris AL and Bicknell R: Enhancement of tumor growth and vascular density by transfection of vascular endothelial cell growth factor into MCF-7 human breast carcinoma cells. Natl Cancer Inst 87: 213-219, 1995.
11. Eisma RJ, Spiro JD and Kreutzer DL: Vascular endothelial growth factor expression in head and neck squamous cell carcinoma. Am J Surg 174: 513-517, 1997.
12. Mineta H, Miura K, Ogino T, Takebayashi S, Misawa K, Ueda Y, Suzuki I, Dictor M, Borg A and Wennerberg J: Prognostic value of vascular endothelial growth factor in head and neck squamous cell carcinomas. Br J Cancer 83: 775-781, 2000.
13. Salven P, Heikkilä P, Anttonen A, Kajanti M and Joensuu H: Vascular endothelial growth factor in squamous cell head and neck carcinoma: expression and prognostic significance. Mod Pathol 10: 1128-1133, 1997.
14. Riedel F, Götte K, Schwalb J, Wirtz H, Bergler W and Hörmann K: Serum levels of vascular endothelial growth factor in patients with head and neck cancer. Eur Arch Otorhinolaryngol 257: 332-336, 2000.
15. Riedel F, Götte K, Schwalb J, Schäfer C and Hörmann K: Expression of vascular endothelial growth factor correlates with angiogenesis and p53 mutations in head and neck squamous cell carcinoma. Acta Otolaryngol 120: 105-111, 2000.
16. Riedel F, Götte K, Bergler W and Hörmann K: Inverse correlation of angiogenic and apoptotic markers in squamous cell carcinoma of the head and neck. Oncol Rep 8: 471-476, 2001.
17. Heldin CH and Westermark B: Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev 79: 1283-1316, 1999.
18. Betsholtz C, Karlsson L and Lindahl P: Developmental roles of platelet-derived growth factors. Bioessays 23: 494-507, 2001.
19. Yu J, Ustach C and Kim HR: Platelet-derived growth factor signaling and human cancer. J Biochem Mol Biol 36: 49-59, 2003.
20. Risau W, Drexler H, Mironov V, Smits A, Siegbahn A, Funa K and Heldin CH: Platelet-derived growth factor is angiogenic in vivo. Growth Factors 7: 261-266, 1992.
21. Pietras K, Ostman A, Sjöquist M, Buchdunger E, Reed RK, Heldin CH and Rubin K: Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors. Cancer Res 61: 2929-2934, 2001.
22. Thommen R, Humar R, Misevic G, Pepper MS, Hahn AW, John M and Battegay EJ: PDGF-BB increases endothelial migration on cord movements during angiogenesis in vitro. J Cell Biochem 64: 403-413, 1997.
23. Druker BJ and Lydon NB: Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemia (Perspective). J Clin Invest 105: 3-7, 2000.
24. Buchdunger E, Cioffi CL, Law N, Stover D, Ohno-Jones S, Druker BJ and Lydon NB: Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-Kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 295: 139-145, 2000.
25. Sjoblom T, Shimizu A, O'Brien KP, Pietras K, Dal Cin P, Buchdunger E, Dumanski JP, Ostman A and Heldin CH: Growth inhibition of dermatofibrosarcoma protuberans tumors by the platelet-derived growth factor receptor antagonist STI571 through induction of apoptosis. Cancer Res 61: 5778-5783, 2001.
26. Petruzelli GJ, Snyderman CH, Johnson JT and Myers EN: Angiogenesis induced by head and neck squamous cell carcinoma xenografts in the chick embryo chorioallantioc membrane model. Ann Otol Rhinol Laryngol 102: 212-221, 1993.
27. Dray TG, Hardin NJ and Sofferman RA: Angiogenesis as a prognostic marker in early head and neck cancer. Ann Otol Rhinol Laryngol 104: 724-729, 1995.
28. Sato N, Beitz JG, Kato J, Yamamoto M, Clark JW, Calabresi P, Raymond A and Frackelton AR Jr: Platelet-derived growth factor indirectly stimulates angiogenesis in vitro. Am J Pathol 142: 1119-1130, 1993.
29. Lindahl P, Bostrom H, Karlsson L, Hellstrom M, Kalen M and Betsholtz C: Role of platelet-derived growth factors in angiogenesis and alveogenesis. Curr Top Pathol 93: 27-33, 1999.
30. Wang D, Huang HJ, Kazlauskas A and Cavenee WK: Induction of vascular endothelial growth factor expression in endothelial cells by platelet-derived growth factor through the activation of phosphatidylinositol 3-kinase. Cancer Res 59: 1464-1472, 1999.
31. Jo N, Mailhos C, Ju M, Cheung E, Bradley J, Nishijima K, Robinson GS, Adamis AP and Shima DT: Inhibition of platelet-derived growth factor B signaling enhances the efficacy of antivascular endothelial growth factor therapy in multiple models of ocular neovascularization. Am J Pathol 168: 2036-2053, 2006.
32. Ball SG, Shuttleworth CA and Kielty CM: Vascular endothelial growth factor can signal through platelet-derived growth factor receptors. J Cell Biol 177: 489-500, 2007.
33. Shen J, Vil MD, Zhang H, Tonra JR, Rong LL, Damoci C, Prewett M, Deevi DS, Kearney J, Surguladze D, Jimenez X, Iacolina M, Bassi R, Zhou K, Balderes P, Mangalampalli VR, Loizos N, Ludwig DL and Zhu Z: An antibody directed against PDGF receptor beta enhances the antitumor and the antiangiogenic activities of an anti-VEGF receptor 2 antibody. Biochem Biophys Res Commun 357: 1142-1147, 2007.
34. Zhang JZ, Maruyama K, Ono I and Kaneko F: Production and secretion of platelet-derived growth factor AB by cultured human keratinocytes: regulatory effects of phorbol 12- myristate 13-acetate, etretinate, 1,25-dihydroxyvitamin D3, and several cytokines. J Dermatol 22: 305-309, 1995.
35. Gleich LL, Srivastava L and Gluckman JL: Plasma platelet-derived growth factor: preliminary study of a potential marker in head and neck cancer. Ann Otol Rhinol Laryngol 105: 710-712, 1996.
36. Ninck S, Reisser C, Dyckhoff G, Helmke B, Bauer H and Herold-Mende C: Expression profiles of angiogenic growth factors in squamous cell carcinomas of the head and neck. Int J Cancer 106: 33-34, 2003.
37. Aebersold DM, Froehlich SC, Jonczy M, Beer KT, Laissue J, Greiner RH and Djonov V: Expression of transforming growth factor-alpha, epidermal growth factor receptor and platelet-derived growth factors A and B in oropharyngeal cancers treated by curative radiation therapy. Radiother Oncol 63: 275-283, 2002.
38. Chang JT, Chen IH, Liao CT, Wang HM, Hsu YM, Hung KF, Lin CJ, Hsieh LL and Cheng AJ: A reverse transcription comparative real-time PCR method for quantitative detection of angiogenic growth factors in head and neck cancer patients. Clin Biochem 35: 591-596, 2002.
39. Li C, Shintani S, Terakado N, Klosek SK, Ishikawa T, Nakashiro K and Hamakawa H: Microvessel density and expression of vascular endothelial growth factor, basic fibroblast growth factor, and platelet-derived endothelial growth factor in oral squamous cell carcinomas. Int J Oral Maxillofac Surg 34: 559-565, 2005.
40. Worden B, Yang XP, Lee TL, Bagain L, Yeh NT, Cohen JG, Van Waes C and Chen Z: Hepatocyte growth factor/scatter factor differentially regulates expression of proangiogenic factors through Egr-1 in head and neck squamous cell carcinoma. Cancer Res 65: 7071-7080, 2005.
41. Beppu K, Jaboine J, Merchant MS, Mackall CL and Thiele CJ: Effect of imatinib mesylate on neuroblastoma tumorigenesis and vascular endothelial growth factor expression. J Natl Cancer Inst 96: 46-55, 2004.
42. Matei D, Kelich S, Cao L, Menning N, Emerson RE, Rao J, Jeng MH and Sledge GW: PDGF BB induces VEGF secretion in ovarian cancer. Cancer Biol Ther 6: 1951-1959, 2007.
43. Vlahovic G, Ponce AM, Rabbani Z, Salahuddin FK, Zgonjanin L, Spasojevic I, Vujaskovic Z and Dewhirst MW: Treatment with imatinib improves drug delivery and efficacy in NSCLC xenografts. Br J Cancer 97: 735-740, 2007.